Efficacy and safety comparison of Helicobacter pylori eradication between vonoprazan dual therapy versus triple therapy: a systematic review and meta-analysis.

ABSTRACT:

Background

As a novel drug, vonoprazan (VPZ) has been developed as a new strategy against Helicobacter pylori (H. pylori) infections. However, whether VPZ + amoxicillin (AMO) dual therapy has a clear advantage is still unclear.

Objective

To review and meta-analyze the available literature investigating the efficacy and safety of H. pylori eradication in VPZ dual therapy.

Design

A systematic review and meta-analysis were conducted.

Data sources and methods

We performed a systematic search in the PubMed, Embase, EIsevier/Science Library, and Cochrane Library databases from 2015 to 2022. Meta-analyses were conducted to evaluate the actual cure rate and the incidence rate of adverse reactions in dual therapy and VPZ + AMO + clarithromycin (CLA)

SUBMITTER: Wang Z 

PROVIDER: S-EPMC9577096 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature